Therapy Areas: Inflammatory Diseases
European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis
18 November 2025 - US-based biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) said on Tuesday that the European Commission has approved BRINSUPRI (brensocatib 25mg tablets) for patients wit...
European Commission approves Celltrion's Remsima IV liquid formulation
18 November 2025 - South Korea-based biopharmaceutical company Celltrion Inc (KRX:068270) announced on Tuesday that the European Commission has granted marketing authorisation for Remsima IV liquid fo...
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
18 November 2025 - Biotheryx Inc, a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, on Monday announced the...
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY
17 November 2025 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Monday that the US Food and Drug Administratio...
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
14 November 2025 - Ionis Pharmaceuticals Inc (Nasdaq:IONS), a US-based provider of RNA-targeted medicines, and Japanese healthcare company Otsuka Pharmaceutical Co Ltd announced on Friday that the Com...
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
12 November 2025 - American clinical-stage biotechnology company Longeveron Inc. (NASDAQ: LGVN) announced on Wednesday that it has received a new United States patent for its proprietary mesenchymal s...